000 02809cam  2200325za 4500
0019.821153
003CaOODSP
00520221107143403
007cr |||||||||||
008160715s2013    onc|||||o    f000 0 eng d
040 |aCaOODSP|beng
041 |aeng|bfre
043 |an-cn---
0861 |aD68-4/126-2013-1E-PDF
1001 |aBouak, F.
24510|aAn efficient mass casualty breathing system for oxygen therapy |h[electronic resource] : |bdetermining the compatibility of the Pulmanex Hi-OX mask with the CAF's in-service oxygen concentrator, POGS 33 / |cby F. Bouak and D.J. Eaton.
260 |a[Ottawa] : |bDefence Research and Development Canada, |cc2013.
300 |axii, 30 p. : |bfigures, graphs, tables.
4901 |aTechnical report ; |v2013-126
500 |a"October 2013."
504 |aIncludes bibliographical references.
520 |aDefence Research and Development Canada was tasked by the Canadian Armed Forces (CAF) Health Services Group Headquarters to develop an efficient mass casualty breathing system for oxygen (O2) therapy in remote areas. This report describes the second phase of the project to assess the performance of the Pulmanex® Hi-OX® mask (HIOX) when combined with the Portable Oxygen Generation System 33C (POGS), the CAF’s in-service O2 concentrator. First, unmanned tests were conducted to determine the quality and the quantity of the POGS product gas. Then, in human trials, nine participants (21 to 58 years) breathed O2 at rest through the HIOX using the POGS as the O2 supply. The test procedure consisted of three breathing periods of 5 min at either 2, 4 or 6 litres per min. Measurements included inhaled and end-tidal fractions of O2 and carbon dioxide, O2 arterial blood saturation, exhaled gas volume, and mask pressure. Subjective ratings of comfort and breathing effort were obtained after each breathing period. The unmanned testing showed that the POGS can safely be used to supply high concentrations of oxygen with no contaminants or toxic gases. Human testing revealed that the HIOX POGS system delivered clinically useful O2 levels. In terms of the measured dependent variables, the results obtained with the POGS proved to be as good as those of the compressed O2. The use of the HIOX with an O2 concentrator will provide sustained O2 with increased efficiency and minimum risks associated with O2 use during CAF medical operations.
69207|2gccst|aTechnical reports
693 4|aOxygen therapy
693 4|aOxygen concentrator
693 4|aChallenges
7001 |aEaton, D. J.
7101 |aCanada. |bDefence R&D Canada.
830#0|aTechnical report (Defence R&D Canada)|v2013-126|w(CaOODSP)9.820558
85640|qPDF|s2.82 MB|uhttps://publications.gc.ca/collections/collection_2016/rddc-drdc/D68-4-126-2013-1-eng.pdf